Dual inhibition of cathepsin G and chymase reduces myocyte death and improves cardiac remodeling after myocardial ischemia reperfusion injury

Basic Research in Cardiology

Volumn 112, Issue 6, 2017, Pages

  Hooshdaran, Bahman ^a   Kolpakov, Mikhail A ^a   Guo, Xinji ^a   Miller, Sonni A ^a   Wang, Tao ^a   Tilley, Douglas G ^a   Rafiq, Khadija ^b   Sabri, Abdelkarim ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cardioprotection; Inflammation; Inflammatory serine proteases; Myocardial ischemia reperfusion

Indexed keywords

CATHEPSIN G; CHYMASE; CHYMASE INHIBITOR; CTSG PROTEIN, MOUSE; ENZYME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIAC MUSCLE CELL; CELL DAMAGE; CELL DEATH; CELL DEGENERATION; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FOCAL ADHESION; HEART FIBROBLAST; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HEART VENTRICLE REMODELING; IMMUNE RESPONSE; INFLAMMATION; MALE; MAST CELL; MOUSE; MUSCLE CELL; MUSCLE FIBRIL; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; SIGNAL TRANSDUCTION; WOUND HEALING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; ENZYMOLOGY; HEART ATRIUM REMODELING; METABOLISM; MYOFIBROBLAST; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; ATRIAL REMODELING; CATHEPSIN G; CHYMASES; ENZYME INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; MYOFIBROBLASTS;

EID: 85029572803     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-017-0652-z     Document Type: Article

References (44)

1. Beghdadi W, Madjene LC, Benhamou M, Charles N, Gautier G, Launay P, Blank U (2011) Mast cells as cellular sensors in inflammation and immunity. Front Immunol 2:37. doi:10.3389/fimmu.2011.00037
2. Caughey GH (2016) Mast cell proteases as pharmacological targets. Eur J Pharmacol 778:44–55. doi:10.1016/j.ejphar.2015.04.045
3. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Investig 106:55–62. doi:10.1172/JCI8768
4. Frangogiannis NG (2012) Regulation of the inflammatory response in cardiac repair. Circ Res 110:159–173. doi:10.1161/CIRCRESAHA.111.243162
5. Fu L, Wei C-C, Powell PC, Bradley WE, Ahmad S, Ferrario CM, Collawn JF, Dell’Italia LJ (2016) Increased fibroblast chymase production mediates procollagen autophagic digestion in volume overload. J Mol Cell Cardiol 92:1–9. doi:10.1016/j.yjmcc.2016.01.019
6. Greco MN, Hawkins MJ, Powell ET, Almond HR, Corcoran TW, de Garavilla L, Kauffman JA, Recacha R, Chattopadhyay D, Andrade-Gordon P, Maryanoff BE (2002) Nonpeptide inhibitors of cathepsin G: optimization of a novel β-ketophosphonic acid lead by structure-based drug design. J Am Chem Soc 124:3810–3811. doi:10.1021/ja017506h
7. Hara M, Matsumori A, Ono K, Kido H, Hwang M-W, Miyamoto T, Iwasaki A, Okada M, Nakatani K, Sasayama S (1999) Mast cells cause apoptosis of cardiomyocytes and proliferation of other intramyocardial cells in vitro. Circulation 100:1443–1449. doi:10.1161/01.cir.100.13.1443
8. Heusch G, Gersh BJ (2017) The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J 38:774–784. doi:10.1093/eurheartj/ehw224
9. Heusch G, Libby P, Gersh B, Yellon D, Bohm M, Lopaschuk G, Opie L (2014) Cardiovascular remodelling in coronary artery disease and heart failure. Lancet (London, England) 383:1933–1943. doi:10.1016/s0140-6736(14)60107-0
10. Heutinck K, ten Berge I, Hack C, Hamann J, Rowshani A (2010) Serine proteases of the human immune system in health and disease. Mol Immunol 47:1943–1955
11. Hoshino F, Urata H, Inoue Y, Saito Y, Yahiro E, Ideishi M, Arakawa K, Saku K (2003) Chymase inhibitor improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol 41:S11–S18 (ISSN print: 0160-2446, accession: 00005344-200301001-00004)
12. Hwang M-W, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A, Hara M, Miyamoto T, Touma M, Sasayama S (2001) Neutralization of interleukin-1b in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol 38:1546–1553. doi:10.1016/S0735-1097(01)01591-1
13. Iacoviello L, Kolpakov V, Salvatore L, Amore C, Pintucci G, de Gaetano G, Donati MB (1995) Human endothelial cell damage by neutrophil-derived cathepsin G. Role of cytoskeleton rearrangement and matrix-bound plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 15:2037–2046. doi:10.1161/01.ATV.15.11.2037
14. Jin D, Takai S, Yamada M, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Miyazaki M (2003) Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res 60:413–420. doi:10.1016/S0008-6363(03)00535-2
15. Kain V, Prabhu SD, Halade GV (2014) Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Res Cardiol 109:444. doi:10.1007/s00395-014-0444-7
16. Kanemitsu H, Takai S, Tsuneyoshi H, Nishina T, Yoshikawa K, Miyazaki M, Ikeda T, Komeda M (2006) Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens Res 29:57–64. doi:10.1291/hypres.29.57
17. Krijnen PAJ, Nijmeijer R, Meijer CJLM, Visser CA, Hack CE, Niessen HWM (2002) Apoptosis in myocardial ischaemia and infarction. J Clin Pathol 55:801–811. doi:10.1136/jcp.55.11.801
18. Kukielka GL, Smith CW, Manning AM, Youker KA, Michael LH, Entman ML (1995) Induction of interleukin-6 synthesis in the myocardium: potential role in postreperfusion inflammatory injury. Circulation 92:1866–1875. doi:10.1161/01.CIR.92.7.1866
19. Levick SP, Meléndez GC, Plante E, McLarty JL, Brower GL, Janicki JS (2011) Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res 89:12–19. doi:10.1093/cvr/cvq272
20. Lindberg BF, Gyllstedt E, Andersson K-E (1997) Conversion of angiotensin I to angiotensin II by chymase activity in human pulmonary membranes. Peptides 18:847–853. doi:10.1016/S0196-9781(97)00011-9
21. Lindstedt KA, Wang Y, Shiota N, Saatinen J, Hyytiainen M, Kokkonen JO, Keski-Oja J, Kovanen PT (2001) Activation of paracrine TGF-β1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase. FASEB J 15:1377–1388. doi:10.1096/fj.00-0273com
22. Mani K (2008) Programmed cell death in cardiac myocytes: strategies to maximize post-ischemic salvage. Heart Fail Rev 13(2):193–209. doi:10.1007/s10741-007-9073-7
23. Maryanoff BE, Garavilla Ld, Greco MN, Haertlein BJ, Wells GI, Andrade-Gordon P, Abraham WM (2010) Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. Am J Resp Crit Care Med 181:247–253. doi:10.1164/rccm.200904-0627OC
24. Meyer-Hoffert U, Wiedow O (2011) Neutrophil serine proteases: mediators of innate immune responses. Curr Opin Hematol 18:19–24. doi:10.1097/MOH.0b013e32834115d1
25. Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM, Lowry AS, Escobar GP, Lucas DG, Yarbrough WM, Zile MR, Spinale FG (2003) Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 107:618–625. doi:10.1161/01.cir.0000046449.36178.00
26. Murphy E, Steenbergen C (2008) Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 88:581–609. doi:10.1152/physrev.00024.2007
27. Nicholls SJ, Hazen SL (2005) Myeloperoxidase and cardiovascular disease. Arter Thromb Vasc Biol 25:1102–1111. doi:10.1161/01.ATV.0000163262.83456.6d
28. Owen CA, Campbell EJ (1998) Angiotensin II generation at the cell Surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition. J Immunol 160:1436–1443 (print ISSN: 0022-1767, online ISSN: 1550-6606)
29. Oyamada S, Bianchi C, Takai S, Chu LM, Sellke FW (2011) Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J Pharmacol Exp Ther 339:143–151. doi:10.1124/jpet.111.179697
30. Pat B, Chen Y, Killingsworth C, Gladden JD, Shi K, Zheng J, Powell PC, Walcott G, Ahmed MI, Gupta H, Desai R, Wei C-C, Hase N, Kobayashi T, Sabri A, Granzier H, Denney T, Tillson M, Dillon AR, Husain A, Dell’Italia LJ (2010) Chymase inhibition prevents fibronectin and myofibrillar loss and improves cardiomyocyte function and LV torsion angle in dogs with isolated mitral regurgitation. Circulation 122:1488–1495. doi:10.1161/circulationaha.109.921619
31. Rafiq K, Hanscom M, Valerie K, Steinberg S, Sabri A (2008) Novel mode for neutrophil protease cathepsin G-mediated signaling: membrane shedding of epidermal growth factor is required for cardiomyocyte anoikis. Circ Res 102:32–41. doi:10.1161/CIRCRESAHA.107.150573
32. Rafiq K, Kolpakov MA, Abdelfettah M, Streblow DN, Hassid A, Dell’Italia LJ, Sabri A (2006) Role of protein-tyrosine phosphatase SHP2 in focal adhesion kinase down-regulation during neutrophil cathepsin G-induced cardiomyocytes anoikis. J Biol Chem 281:19781–19792. doi:10.1074/jbc.M513040200
33. Sabri A, Alcott SG, Elouardighi H, Pak E, Derian C, Andrade-Gordon P, Kinnally K, Steinberg SF (2003) Neutrophil cathepsin G promotes detachment-induced cardiomyocyte apoptosis via a protease-activated receptor-independent mechanism. J Biol Chem 278:23944–23954. doi:10.1074/jbc.M302718200
34. Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA (2000) The neutrophil as a cellular source of chemokines. Immunol Rev 177:195–203. doi:10.1034/j.1600-065X.2000.17706.x
35. Sharony R, Yu P-J, Park J, Galloway A, Mignatti P, Pintucci G (2010) Protein targets of inflammatory serine proteases and cardiovascular disease. J Inflamm 7:45. doi:10.1186/1476-9255-7-45
36. Tchougounova E, Lundequist A, Fajardo I, Winberg J-O, Åbrink M, Pejler G (2005) A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 280:9291–9296. doi:10.1074/jbc.M410396200
37. Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC (2016) Cardiac fibrosis: the fibroblast awakens. Circ Res 118:1021–1040. doi:10.1161/circresaha.115.306565
38. van den Borne SWM, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J (2010) Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol 7:30–37. doi:10.1038/nrcardio.2009.199
39. Vander Heide RS, Steenbergen C (2013) Cardioprotection and myocardial reperfusion: pitfalls to clinical application. Circ Res 113:464–477. doi:10.1161/circresaha.113.300765
40. Wiedow O, Meyer-Hoffert U (2005) Neutrophil serine proteases: potential key regulators of cell signalling during inflammation. J Intern Med 257:319–328. doi:10.1111/j.1365-2796.2005.01476.x
41. Wilson TJ, Nannuru KC, Singh RK (2009) Cathepsin G-mediated activation of pro-matrix metalloproteinase 9 at the tumor-bone interface promotes transforming growth factor-β signaling and bone destruction. Mol Cancer Res 7:1224–1233. doi:10.1158/1541-7786.mcr-09-0028
42. Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121–1135. doi:10.1056/NEJMra071667
43. Zhao X-Y, Zhao L-Y, Zheng Q-S, Su J-L, Guan H, Shang F-J, Niu X-L, He Y-P, Lu X-L (2008) Chymase induces profibrotic response via transforming growth factor-β1/Smad activation in rat cardiac fibroblasts. Mol Cell Biochem 310:159–166. doi:10.1007/s11010-007-9676-2
44. Zheng J, Wei C-C, Hase N, Shi K, Killingsworth CR, Litovsky SH, Powell PC, Kobayashi T, Ferrario CM, Rab A, Aban I, Collawn JF, Dell’Italia LJ (2014) Chymase mediates injury and mitochondrial damage in cardiomyocytes during acute ischemia/reperfusion in the dog. PLoS One 9:e94732. doi:10.1371/journal.pone.0094732